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Centre for Health Economics, University of York, York, UKA B S T R A C TBackground: There has been some controversy on whether the costs
of omalizumab outweigh its beneﬁts for severe persistent allergic
asthma. Objectives: This study aimed to resolve the uncertainties
and limitations of previous analyses and establish the cost-
effectiveness of omalizumab under the list price and Patient Access
Scheme (PAS) discounted price for the UK National Health Service.
Methods: A decision-analytic model was developed to evaluate the
long-term cost-effectiveness of omalizumab under the perspective of
the National Health Service. Outcomes were expressed as quality-
adjusted life-years (QALYs). Patient subgroups were deﬁned post hoc
on the basis of data collected in clinical trials: previous hospital-
ization, on maintenance oral corticosteroids, and three or more
previous exacerbations. Results: The incremental cost-effectiveness
ratio varied from £30,109 to £57,557 per QALY gained depending on
the population considered using the PAS price; incremental cost-
effectiveness ratios were over a third higher using the list price.
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r Inc.
1016/j.jval.2014.07.009
sdefaria@york.ac.uk.
ndence to: Rita Faria, Centre for Health Economicsper QALY gained in the severe subgroups if the improvement in
health-related quality of life from omalizumab is mapped from an
asthma-speciﬁc measure to the EuroQol ﬁve-dimensional question-
naire (vs. the EuroQol ﬁve-dimensional questionnaire directly col-
lected from patients) or asthma mortality refers to death after
hospitalization from asthma (vs. asthma-mortality risk in the com-
munity). Conclusions: Although the cost-effectiveness of omalizu-
mab is more favorable under the PAS price, it represents good value
for money only in severe subgroups and under optimistic assump-
tions regarding asthma mortality and improvement in health-related
quality of life. For these reasons, omalizumab should be carefully
targeted to ensure value for money.
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omalizumab.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Asthma affects more than 300 million people worldwide [1].
Approximately 20% have severe asthma, of which 20% is poorly
controlled [2]. Patients with poorly controlled asthma endure poor
quality of life and experience increased risk of asthma exacerba-
tions [1]. An exacerbation is a severe onset of symptoms (difﬁculty
breathing, wheezing, cough, tight chest) that may require hospital
treatment and may be life threatening. In 2011, in England there
were more than 82,000 hospitalizations for asthma, of which 68%
were accident and emergency admissions [3]. Asthma treatment
follows a stepwise approach to achieve and maintain control of
symptoms while minimizing adverse effects [1,4]. Treatment is
stepped up until control is achieved and stepped down if more
intense therapy is no longer required. Patients with severe asthma
require treatment at step 4—daily use of high doses of inhaled
steroids—or step 5—continuous or frequent use of oral cortico-
steroids (OCS). Adverse effects from long-term use of OCS include
adrenal suppression, osteoporosis, cataracts, and diabetes [1,5].
Omalizumab has been shown to have a positive beneﬁt-risk proﬁle
in that it reduces the risk of exacerbations and improves health-
related quality of life (HRQOL) [6–8]. Serious adverse events are rare
(frequency o1/10,000); the most frequent adverse events areheadache, upper abdominal pain, fever, and infection site reactions
[6]. Hence, omalizumab offers an alternative to moving up to
maintenance OCS (step 5) for patients uncontrolled at step 4 and
may allow a reduction in the dose of OCS in patients controlled at
step 5 (who would otherwise be uncontrolled at step 4).
There has been some controversy on whether the beneﬁts of
omalizumab are outweighed by its costs [7–13]. In the United
Kingdom, omalizumab was assessed by the Scottish Medicines
Consortium (SMC) for the National Health Service (NHS) in Scot-
land [14] and by the National Institute for Health and Care
Excellence (NICE) for the NHS in England and Wales [7,8]. The
SMC recommended omalizumab for patients 12 years and older
on maintenance OCS and in whom all other treatments have failed
[15]; this recommendation was extended to children aged 6 to 11
years after the inclusion of this age group in the product license
[16]. NICE assessed omalizumab for patients aged 12 years and
older and for patients aged 6 to 11 years in two separate technology
appraisals (TAs). In TA133, in 2007, NICE recommended omalizu-
mab for patients aged 12 years and older with severe unstable
disease who are at an elevated risk of asthma mortality [7]. TA201,
which assessed omalizumab in patients aged 6 to 11 years in 2010,
did not recommend omalizumab because the incremental cost-
effectiveness ratios (ICERs) were well above conventionalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Even for more severe patients, deﬁned as those experiencing at
least three exacerbations in the previous year, the ICER was £82,600
per quality-adjusted life-year (QALY) gained. In 2012, NICE decided
to review these recommendations by commissioning a new
appraisal on the clinical effectiveness and cost-effectiveness of
omalizumab for severe persistent allergic asthma in both adults
and children.
This study reports the independent cost-effectiveness assess-
ment of omalizumab for severe persistent allergic asthma for the
entire licensed population and subgroups using both the list price
and the discounted Patient Access Scheme (PAS) price, details of
which are conﬁdential. Therefore, it provides important information
to assist clinicians and other reimbursement agencies in optimizing
the position of omalizumab on the basis of clinical effectiveness and
cost-effectiveness considerations and the role that formal or infor-
mal price negotiation with the manufacturer might play. In addition,
it builds on the previous assessments by addressing the key areas of
uncertainty identiﬁed from previous TAs and published cost-
effectiveness analyses, by exploring the sensitivity of the results to
the major drivers of cost-effectiveness and by examining whether
there are more severe patient subgroups for which omalizumab
represents good value for money. Full details on the NICE technology
appraisal can be found at http://www.nice.org.uk/guidance/ta278.Methods
Overview
The cost-effectiveness of omalizumab was evaluated by compar-
ing the additional costs of omalizumab add-on therapy to its
additional beneﬁts in terms of improvement in HRQOL and
reduction in exacerbations compared with standard care alone
over a lifetime horizon. Standard care included optimized therapy
at step 4 or 5. Health outcomes were expressed in QALYs. Costs
were expressed in UK pound sterling at a 2010 price base from the
perspective of the NHS. Both costs and QALYs were discounted at
3.5% per annum as per NICE recommendations [17]. Systematic
reviews evaluated the evidence on the effectiveness and safety of
omalizumab; these are reported in detail elsewhere [18]. All stages
of the work were informed by discussions with clinical advisors.
Population and Subgroups
The population reﬂects the European Union/UK product license
and corresponds to the patient populations enrolled in the
randomized controlled trials (RCTs) assessing the clinical effec-
tiveness of omalizumab: patients uncontrolled at step 4 and in the
process of moving up to step 5 and patients controlled at step 5
whose asthma would be uncontrolled if they were on step 4
therapy, presented separately by age (adults and adolescents aged
Z12 years and children aged 6–11 years) [6,19–21]. Patient sub-
groups were deﬁned according to different indicators of severity,
which were informed by both clinical and economic considera-
tions on the basis of subgroups evaluated in the previous NICE
and SMC appraisals: 1) number of hospitalizations in the past year
due to an exacerbation (hospitalization subgroup as per TA133), 2)
maintenance OCS use (maintenance OCS subgroup as per SMC
recommendations), and 3) three or more exacerbations in the year
before trial enrolment (Z3 exacerbations as per TA201).
The Technology
Omalizumab 75-mg (or 150-mg) solution for subcutaneous injection
is licensed in patients aged 12 years and older with severe persistent
allergic asthma who have a positive skin test result or in vitro
reactivity to a perennial aeroallergen, who have reduced lungfunction as well as frequent daytime symptoms or night-time
awakenings, and who have had multiple documented severe
asthma exacerbations despite daily high-dose inhaled corticoste-
roids, plus a long-acting inhaled beta2-agonist [6]. It is licensed in
children aged 6 to 11 years with severe persistent allergic asthma
who have a positive skin test result or in vitro reactivity to a
perennial aeroallergen and frequent daytime symptoms or night-
time awakenings and who have had multiple documented severe
asthma exacerbations despite daily high-dose inhaled corticoste-
roids, plus a long-acting inhaled beta2-agonist. The dose depends
on the patient’s weight and serum concentration of immunoglobin
E at treatment initiation. Patients should be assessed at 16 weeks for
response to treatment before further injections are administered.
Modeling Approach
The model is a cohort Markov model developed in MS Excel 2010
with three health states (day-to-day asthma symptoms with and
without omalizumab, asthma death, and other-cause death) and two
events (clinically signiﬁcant severe [CSS] and clinically signiﬁcant
nonsevere [CSNS] exacerbations). This model was built to inform the
NICE guidance on omalizumab and adapted and reanalyzed for the
purposes of this study. Patients start in the day-to-day asthma
symptoms state on either omalizumab add-on therapy or standard
therapy alone. At 16 weeks, patients on omalizumab are assessed for
response to treatment, at which point omalizumab responders are
separated from nonresponders, as per product license [6]. Respond-
ers remain on omalizumab for the period of treatment duration
while nonresponders are assumed to revert to standard care alone.
The cycle length is 16 weeks for the ﬁrst cycle and 3 months
subsequently. During each cycle, patients in the day-to-day symp-
tom state have an elevated risk of asthma mortality and a risk from
death from other causes as in the general UK population. Table 1 in
Appendix 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2014.07.009 summarizes and justiﬁes the key model as-
sumptions, and Supplemental Figure 1 presents the model structure.
Model Inputs
Table 1 presents model inputs for the base-case population (equiv-
alent tables for each subgroup population are provided in Tables
S2–S4 in Appendix 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.07.009). Model inputs were mostly based
on evidence from the three RCTs conducted in the European Union/
UK licensed population that include assessment of response to
treatment—The INvestigatioN of Omalizumab in seVere Asthma
TrEatment (INNOVATE) [20], Evaluate Xolair for Asthma as Leading
Treatment (EXALT) [19], and IA-05 European Union Population (IA-
05 EUP) [21]—which are summarized in Table 2. Systematic reviews
were conducted to identify relevant studies for asthma mortality,
HRQOL improvement with omalizumab, and HRQOL decrement
from an exacerbation; these are reported in detail elsewhere [18].
Effectiveness and safety
Omalizumab is modeled to reduce the risk of both CSS and CSNS
exacerbations, which, in turn, reduces the risk of asthma death,
and to improve HRQOL. The risk ratio for CSS and CSNS
exacerbations in patients aged 6 to 11 years observed in IA-05
EUP between responders and patients allocated to placebo was
0.2494 (95%CI 0.1425–0.4362) and 0.5089 (0.3291–0.7869), respec-
tively. INNOVATE was used for the base case because its double-
blind placebo-controlled design confers it a lower risk of bias than
EXALT (open-label non–placebo-controlled). The proportion of
responders corresponds to the proportion of responders observed
in the RCTs (IA-05 EUP for patients aged 6–11 years at 74.2% and
INNOVATE for patients aged 12 years and older at 56.5%). Res-
ponders are assumed to experience the exacerbation rates and
Fig. 1 – Effect of asthma mortality on the cost-effectiveness of omalizumab. The asthma mortality risk is expressed as a
yearly rate; that is, a risk of 1% reads as 1 death over 100 persons-years. Subgroups with three or more exacerbations are not
shown because the curves overlap the other subgroups and the overall population. ICER, incremental cost-effectiveness ratio;
OCS, oral corticosteroid; QALY, quality-adjusted life-year.
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whereas nonresponders, who revert to standard care, are assumed
to experience the same exacerbation rates and HRQOL as patients
randomized to the standard care arm of the trials. Treatment
duration was assumed as 10 years as per TA201 and advice from
clinical experts [7]. After treatment discontinuation, patients who
were on omalizumab were assumed to experience the exacerba-
tion rates and HRQOL of patients on standard care.
Rates of adverse events in the RCTs were generally low and
similar between treatment groups (omalizumab add-on therapy
and standard therapy alone), including serious adverse events
such as death and anaphylaxis [6,19–21]. Therefore, no adverse
events from omalizumab were included in themodel. The adverse
events related to the long-term use of maintenance OCS, how-
ever, were included in a scenario following clinical advice because
of their signiﬁcant cost and HRQOL implications [5].
Asthma mortality
The systematic review on asthma mortality identiﬁed two potential
sources for the asthma mortality risk experienced by patients in the
United Kingdom: de Vries et al. [22] and Watson et al. [23]. De Vries
et al. [22] report asthmamortality by treatment step from a large UK
NHS primary care database. Watson et al. [23] report the all-cause
mortality for patients hospitalized for asthma and acute severe
asthma by age band. The asthma mortality for patients at step 5
from de Vries et al. was used for the base case because it represents
the asthmamortality risk faced by themost severe patients. Watson
et al. was used for the scenario because it is not speciﬁc for patientswith severe persistent allergic asthma (the licensed population for
omalizumab) and does not include deaths in the community.
HRQOL values
The systematic review did not identify additional sources of
HRQOL utilities in the licensed population over and above those
reported in INNOVATE and EXALT. Although EXALT is at greater
risk of bias from its open-label non–placebo-controlled design, it
was preferred for the base case because it collected EuroQol ﬁve-
dimensional questionnaire (EQ-5D) values directly from patients
[19,24]. The difference in EQ-5D values between omalizumab
responders and patients on standard care in the overall EXALT
population was 0.048, 0.13 for the hospitalization subgroup, 0.105
for the maintenance OCS subgroup, and 0.042 in the three or
more exacerbations subgroup. The mapped EQ-5D values from the
Asthma Quality of Life Questionnaire collected in INNOVATE,
obtained from the manufacturer’s submission to NICE, were used
in a scenario [24,25,26]. The difference in the mapped EQ-5D values
from INNOVATE was 0.110 for the overall population, 0.138 for the
hospitalization subgroup, 0.106 for the maintenance OCS sub-
group, and 0.136 for the three or more exacerbations subgroup.
Patients aged 6 to 11 years on omalizumab were assumed to
experience the same improvement in HRQOL as patients aged 12
years and older. Although the improvement in HRQOL observed in
IA-05 EUP was not signiﬁcant, there was evidence of a positive
change and no clear clinical reason why symptomatic improve-
ments would differ by age [21]. Therefore, children are assumed to
experience the same HRQOL improvements as adults and
Table 1 – Model inputs for overall patient population.
Variables Adults and adolescents (patients aged Z12 y) Children (patients aged 6–11 y) Distribution for
probabilistic
sensitivity analysisValue (95% conﬁdence interval*
or standard error)
Source Value (95% conﬁdence interval
or standard error)
Source
Baseline rate of exacerbations†
CSNS exacerbations 0.8046 (0.6552–0.9881) INNOVATE‡
[18,20,24]
1.5648 (1.2248–1.9992) IA-05 EUP§ [18,21,24] Log normal
CSS exacerbations 0.8842 (0.7268–1.0756) INNOVATE
[18,20,24]
0.4645 (0.2963–0.7283) IA-05 EUP [18,21,24] Log normal
Treatment effectiveness
Proportion of responders (%) 56.5 (49.74–63.18) INNOVATE
[18,20,24]
74.2 (67.41–81.01) IA-05 EUP [18,21,24] Beta
Risk ratio for CSNS
exacerbations (responders)
0.5089 (0.3291–0.7869) INNOVATE
[18,20,24]
0.2415 (0.1511–0.3861) IA-05 EUP [18,21,24] Log normal
Risk ratio for CSS exacerbations
(responders)
0.2494 (0.1425–0.4362) INNOVATE
[18,20,24]
0.3051 (0.1380–0.6743) IA-05 EUP [18,21,24] Log normal
Mortalityǁ
All-cause mortality UK life-tables adjusted for asthma-
related deaths
ONS [38] UK life-tables adjusted for asthma-
related deaths
ONS [8] Deterministic
Asthma-related mortality Asthma-related mortality rate ¼ 0.4
per 100 person-years
De Vries et al.
[22]
Asthma-related mortality rate ¼ 0.4
per 100 person-years
De Vries et al. [22] Deterministic
Probability over one cycle (3 mo) ¼
0.001
Probability over one cycle (3 mo) ¼
0.001
HRQOL¶
Omalizumab effect# HRQOL difference observed in the
trial
EXALT** [19,24] As per adults and adolescents EXALT [19,24] Beta
0.767 (SE ¼ 0.02) (omalizumab) vs.
0.719
(SE ¼ 0.026) (standard care)
HRQOL loss due to
exacerbations
CSNS ¼ 0.10 (SE ¼ 0.05) Lloyd et al. [27] As per adults and adolescents Lloyd et al. [27] Gamma
CSS ¼ 0.20 (SE ¼ 0.1)
Duration of exacerbation 4 wk Deterministic
Resource use and costs
Resources used during an CSNS
exacerbation
N ¼ 195 CSNS exacerbations INNOVATE
[18,20,24]
N ¼ 244 CSNS exacerbations IA-05 EUP [18,21,24] Gamma
45 (23%) GP ofﬁce appointments. 163 (67%) GP ofﬁce visits
7 (4%) hospital outpatient
appointments
1 GP home visit
9 (5%) admissions to accident and
emergency (A&E)
53 (22%) hospital outpatient
appointments
17 (9%) hospitalizations in the
general ward
66 (27%) admissions to A&E
37 (15%) hospitalizations in the
general ward
Resources used during a CSS
exacerbation
N ¼ 204 CSS exacerbations INNOVATE
[18,20,24]
N ¼ 76 CSS exacerbations IA-05 EUP [18,21,24] Gamma
34 (17%) GP ofﬁce appointments 51 (67%) GP ofﬁce appointments
2 (1%) GP home appointments 16 (22%) hospital outpatient
appointments
continued on next page
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Table 1 – continued
Variables Adults and adolescents (patients aged Z12 y) Children (patients aged 6–11 y) Distribution for
probabilistic
sensitivity analysisValue (95% conﬁdence interval*
or standard error)
Source Value (95% conﬁdence interval
or standard error)
Source
7 (7%) hospital outpatient
appointments
21 (27%) admissions to A&E
14 (7%) admissions to A&E 11 (15%) hospitalizations in the
general ward
27 (13%) hospitalizations in the
general ward
Cost of exacerbations CSNS ¼ £87.7 NHS reference
costs [28]
CSNS ¼ CSS ¼ £213.89 NHS reference costs
[28]
Unit costs are
deterministic
CSS ¼ £124.32 PSSRU unit
costs [29]
PSSRU unit costs
[29]
Routine visits 2 per year, £160 each NHS reference
costs [28]
2 per year, £190 each NHS reference costs
[28]
Unit costs are
deterministicInitiation of therapy £245 £247
Standard therapy costs (per year) £1197 INNOVATE
[18,20,24]
£810 IA-05 EUP [18,21,24] NA
Omalizumab costs (per year) £8056 INNOVATE
[18,20,24]
£8,455 IA-05 EUP [18,21,24] NA
Administration and monitoring
costs
First year: £260 INNOVATE
[18,20,24]
First year: £268 IA-05 EUP [18,21,24] NA
Thereafter: £146 NHS reference
costs [28]
Thereafter: £151 NHS reference costs
[28]
CSNS, clinical signiﬁcant nonsevere exacerbation; CSS, clinical signiﬁcant severe exacerbation; EQ-5D, EuroQol ﬁve-dimensional questionnaire; EXALT, Evaluate Xolair for Asthma as Leading
Treatment; GP, general practitioner; HRQOL, health-related quality of life; IA-05 EUP, IA-05 European Union Population; INNOVATE, The INvestigatioN of Omalizumab in seVere Asthma
TrEatment; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; ONS, Ofﬁce of National Statistics; PAS, Patient Access Scheme; PSSRU, Personal Social Services
Research Unit; RCT, randomized controlled trial; SE, standard error.
* The 95% conﬁdence interval is shown when the distribution can be assumed to be normal.
† The exacerbation rates were calculated by dividing the number of person-years in the trial by the number of exacerbations, which assumes that the exacerbation rate is constant over time.
‡ INNOVATE was a double-blind RCT including adults and adolescents aged 12 y and older but did not collect a generic measure of HRQOL [18].
§ IA-05 EUP was a predeﬁned subgroup of the IA-05 RCT that consisted of the licensed pediatric population (6 -11 y) [19]. IA-05EUP did not collect a generic measure of HRQOL.
|| The mortality rates were converted to a probability over the cycle length using the method proposed by Briggs et al. [32].
¶ HRQOL for day-to-day asthma symptoms for omalizumab compared with standard therapy is informed by EQ-5D data collected at 32 wk in EXALT between responders and patients allocated
to standard therapy (reported in the manufacturer's submission to NICE).
# The cost of omalizumab shown is based on its list price; the PAS price is conﬁdential.
** EXALT was an open-label RCT in the population aged 12 y and older and collected EQ-5D data directly from patients [17].
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Table 2 – Summary of randomized controlled trials used in the assessment.
Characteristic Study
INNOVATE [20] EXALT [19] IA-EUP [20]
Population Adults and adolescents aged
12 y and older
Adults and adolescents aged
12 y and older
Children aged 6–11 y
Comparator Placebo No omalizumab Placebo
Blinding Double-blind Open-label Double-blind
Duration (wk) 28 32 24 þ 28
Assessment of response Global Evaluation of Treatment
Effectiveness
Global Evaluation of Treatment
Effectiveness
Global Evaluation of Treatment
Effectiveness
Time point of assessment of
response (wk)
28 16 52
Measure of health-related
quality of life
Asthma Quality of Life
Questionnaire
EQ-5D Pediatric Asthma Quality of Life
Questionnaire
Proportion of responders (%) 57 70 74
Reduction in exacerbations Positive and statistically
signiﬁcant
Positive and statistically
signiﬁcant
Positive and statistically
signiﬁcant
Improvement in health-related
quality of life
Signiﬁcant improvement Signiﬁcant improvement Nonsigniﬁcant improvement
Note. Global Evaluation of Treatment Effectiveness is a tool to measure response to treatment on a ﬁve-point scale. A score of excellent or good
indicates adequate response to treatment.
EQ-5D, EuroQol ﬁve-dimensional questionnaire; EXALT, Evaluate Xolair for Asthma as Leading Treatment; INNOVATE, The INvestigatioN of
Omalizumab in seVere Asthma TrEatment; IA-EUP, IA-05 European Union Population.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 7 2 – 7 8 2 777adolescents. Only one study was found with utility values for
HRQOL decrement from an exacerbation [27]. The HRQOL decre-
ment from an exacerbation was assumed to last 4 weeks.
Resource use and costs
The model considered costs relating to omalizumab therapy, costs
relating to standard care, and costs from exacerbations. Resource
use is based on data collected in INNOVATE and IA-05 EUP
[20,21,24]; unit costs were obtained from published sources [28,29].
Costs associated with omalizumab therapy included the costs of the
drug and the costs of administration and monitoring. The average
annual cost of omalizumab was based on the distribution of doses
used by patients in the trials. The omalizumab list price is £256.15
for 150-mg preﬁlled syringe and £128.07 for 75 mg [30]. The
manufacturer and the UK Department of Health, however, agreed
on a discounted PAS price, details of which are conﬁdential. The PAS
consists of a pricing agreement between the manufacturer and the
UK Department of Health designed to improve the cost-
effectiveness proﬁle of a new technology and facilitate patient
access. Without the PAS price, the annual cost of omalizumab
including administration and monitoring for the ﬁrst year based on
INNOVATE was £8316 (adults and adolescents) and based on IA-04
EUP (children aged 6–11 years ) was £8723; subsequent year’s cost
was £8202 and £8606, respectively.
Analytical Methods
The cost-effectiveness of omalizumab was estimated using con-
ventional decision rules and reported as an ICER [31]. The ICER
represents the additional cost of omalizumab over standard care
for each additional QALY gained. All results are probabilistic in
that ICERs are based on expected values and uncertainty is
expressed in terms of probability that omalizumab is cost-
effective at conventional thresholds of cost-effectiveness [17,32].
Uncertainty Analysis
The uncertainty analysis aimed to address the key areas of
uncertainty and potential limitations identiﬁed from the previous
evaluations of omalizumab. The population subgroups address theoverall positioning of omalizumab in the stepwise therapy for
asthma. Three scenarios were considered: 1) using the HRQOL
improvement in EQ-5D values mapped from the Asthma Quality
of Life Questionnaire collected in INNOVATE at 28 weeks [24–26], 2)
using asthma-related mortality associated with a hospitalization for
asthma [23], and 3) including the steroid-sparing potential of
omalizumab [24]. Scenarios 1 and 2 were presented for the entire
population and the three subgroups by age (patients aged 6–11 years
and patients aged 12 years and older); scenario 3 is presented only
for the maintenance OCS subgroup (aged 12 years and older). In this
scenario, patients on standard care and patients who discontinued
omalizumab incurred health losses and additional costs. In the
absence of estimates of health losses in terms of QALYs, the health
burden expressed in disability-adjusted life-years was used as a
proxy for the QALYs lost because of long-term use of OCS [24].Results
Base-Case and Subgroup Populations
Table 3 presents the cost-effectiveness results for the base-case and
subgroup populations with and without the PAS price. The ICERs
using the PAS price are above the conventional thresholds used by
NICE of £20,000 to £30,000 per additional QALY in the overall
population and three or more exacerbations subgroup, but closer to
the upper threshold in the hospitalization and maintenance OCS
subgroups. The ICERs using the list price are all above £40,000 per
QALY and approximately £80,000 for the overall population. The
probability that omalizumab is cost-effective at a threshold of £30,000
per QALY is zero across the base-case populations and subgroups
except the hospitalization (0.24 for adults; 0.52 for children) and
maintenance OCS subgroups (0.21). The probability is zero for the
analysis with the list price. The lower ICER obtained for children
reﬂects their greater exacerbation rates, the higher proportion of
responders, and the more pronounced reduction in exacerbations.
The cost-effectiveness of omalizumab is improved in the
hospitalization and in the maintenance OCS subgroups for two
reasons. First, the improvement in HRQOL with omalizumab is
Table 3 – Cost-effectiveness results for base-case and scenario analysis.
Scenario ICER omalizumab þ standard care vs. standard care (£/QALY) (probability that
omalizumab is cost-effective at £20,000 and £30,000/QALY)
Overall
population
Hospitalization
subgroup
Maintenance
OCS
subgroup
Z3
exacerbations
Z12 y 6–11 y Z12 y 6–11 y Z12 y Z12 y 6–11 y
Analysis with omalizumab with the patient access scheme discount
Base case 57,557
(0; 0)
53,348
(0; 0)
31,782
(0; 0.24)
30,109
(0; 0.52)
34,386 (0; 0.21) 53,087
(0; 0)
48,537
(0; 0)
1. HRQOL improvement The EQ-5D mapped
from the AQLQ collected in INNOVATE at
28 wk [24–26]
35,825
(0; 0.03)
34,441
(0; 0.04)
30,299 (0;
0.45)
28,833
(0; 0.64)
34,735 (0; 0.11) 28,359
(0; 0.66)
27,096
(0; 0.84)
2. Asthma mortality Death after
hospitalization for asthma in the United
Kingdom per age applied to severe
exacerbation event (o12 y, 0.097%; 12–16
y, 0.319%; 17–44 y, 0.383%; and 45 y and
older, 2.478%) [23]
31,949
(0; 0.28)
67,448
(0; 0)
21,920
(0.20;
0.99)
32,218
(0; 0.15)
20,769 (0.43; 0.96) 26,654
(0.01;
0.81)
56,214
(0; 0)
3. Steroid sparing Health burden (0.02331
QALYs lost per patient per year) and
costs (£205.60 per patient per year) from
long-term use of OCS [24]
NA NA NA NA 28,102
(deterministic)
NA NA
Analysis with omalizumab list price
Base case 83,822
(0; 0)
78,009
(0, 0)
46,431 (0;
0)
44,142
(0; 0)
50,181 (0; 0) 77,868
(0; 0)
76,149
(0; 0)
1. HRQOL improvement The EQ-5D mapped
from the AQLQ collected in INNOVATE at
28 wk [24–26]
52,236
(0; 0)
50,229
(0; 0)
44,430 (0;
0)
42,296
(0; 0)
50,068 (0; 0) 43,523
(0; 0)
41,429
(0; 0)
2. Asthma mortality Death after
hospitalization for asthma in the United
Kingdom per age applied to severe
exacerbation event (o12 y, 0.097%; 12–16
y, 0.319%; 17–44 y, 0.383%; and 45 y and
older, 2.478%) [23]
46,029
(0; 0)
98,688
(0; 0)
31,575
(0; 0.30)
47,430
(0; 0)
29,657 (0; 0.58) 38,302
(0; 0)
83,004
(0; 0)
3. Steroid sparing Health burden (0.02331
QALYs lost per patient per year) and
costs (£205.60 per patient per year) from
long-term use of OCS [24]
NA NA NA NA 46,634 NA NA
Note. The steroid-sparing scenario was conducted only on the maintenance OCS subgroup in the deterministic model given the absence of
standard errors for the point estimates.
AQLQ, Asthma Quality of Life Questionnaire; EQ-5D, EuroQol ﬁve-dimensional questionnaire; HRQOL, health-related quality of life; ICER,
incremental cost-effectiveness ratio; INNOVATE, The INvestigatioN of Omalizumab in seVere Asthma TrEatment; NA, not applicable; OCS, oral
corticosteroid; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 7 2 – 7 8 2778greater. Second, although the reduction in exacerbations is similar,
the subgroups are at a greater risk of exacerbations. In contrast, the
ICER for the three or more exacerbations subgroup is similar to that
for the overall population due to a similar improvement in HRQOL.
Uncertainty Analysis
Table 3 also presents the results of the scenario analysis. Using
EQ-5D values mapped from the Asthma Quality of Life Question-
naire collected in INNOVATE decreased the ICER in all popula-
tions but the maintenance OCS subgroup. This reﬂects the
difference in HRQOL improvement in the EQ-5D directly meas-
ured in EXALT compared with INNOVATE. The incorporation of
adverse effects from OCS has little impact on the ICER for the
maintenance OCS subgroup. Two reasons may explain this effect.
First, the estimates of burden from the quantiﬁable adverse
events from long-term use of OCS are small at 0.023 QALYs lostand £205.60 additional costs per year and are likely to be an
underestimate of the lifetime burden of OCS. Second, the QALY
loss and additional costs are applied to patients after the
discontinuation of treatment with omalizumab. In other words,
patients on omalizumab do not incur the health losses and
additional costs associated with long-term use of OCS only
during the 10 years of treatment with omalizumab. Asthma
mortality has a dual effect on the ICER depending on the
population: the ICER is almost halved for adults and adolescents,
whereas it increases for children. The mortality risk for adults
older than 45 years in Watson et al. is greater than the risk
reported in de Vries et al.; therefore, the ICER falls. For children
younger than 11 years, the mortality risk in Watson et al. is much
lower than the assumed mortality risk from de Vries et al.;
therefore, the ICER increases. It is difﬁcult to compare the asthma
mortality reported in de Vries et al. with that reported in Watson
et al. directly because de Vries et al. report a rate per 100 persons-
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 7 2 – 7 8 2 779years and Watson et al. report a probability of death after a
hospitalization for asthma.
Figure 1 illustrates the effect of the asthma mortality risk on
the ICER for the overall populations and hospitalization and
maintenance OCS subgroups (the subgroups with the lowest ICER
across the subgroup populations) under the PAS price. The ICER
decreases with an increase in asthma mortality risk. Omalizumab
meets the higher cost-effectiveness threshold if asthma mortality
risk exceeds 1.70% in the overall population and plateaus around
£20,000/QALY at a risk above 2%, which corresponds to 2 asthma
deaths in 100 patients over 1 year. The asthma-mortality risk
needed to lower the ICER below £30,000/QALY is much smaller in
the severe subgroups: 0.4% in the hospitalization subgroup for
children, 0.55% in the hospitalization subgroup for adults, and
0.70% in maintenance OCS subgroups.
Figure 2 shows the effect of improvements in HRQOL of the
day-to-day symptom state on the ICER for the overall populations
and hospitalization and maintenance OCS subgroups under
the PAS price. As expected, the ICER decreases with an increase
in HRQOL improvement with omalizumab. The ICER is below
£30,000 per QALY gained when the HRQOL improvement with
omalizumab is above 0.13 for the overall populations and sub-
groups. This is almost three times greater than the improvement
observed in EXALT for the overall population (0.048) but similar to
that in the hospitalization subgroup in the same trial. An ICER
below £20,000 is achieved only with improvements in HRQOL
above 0.21, which would make the HRQOL for the overall pop-
ulation at 0.92, close to the population norm for this age group [33].Fig. 2 – Effect of improvements in health-related quality of life o
three or more exacerbations are not shown because the curves
5D, EuroQol ﬁve-dimensional questionnaire; ICER, incremental c
quality-adjusted life-year.Discussion
Main Findings
Omalizumab improves the health outcomes of patients with
severe persistent asthma but at greater costs to the NHS. In
contrast, using the PAS price and under conventional NICE
thresholds of cost-effectiveness, omalizumab may be a cost-
effective use of NHS resources for more severe population
subgroups. The lower ICERs in the severe population subgroups
(and therefore more favorable toward omalizumab) reﬂect the
greater HRQOL improvement in day-to-day asthma symptoms
conferred by omalizumab, and to a lesser extent, the greater risk
of exacerbations faced by more severe populations. The cost-
effectiveness of omalizumab is improved under the proposed PAS
price compared with the standard list price because the ICERs are
reduced by at least a third.
The cost-effectiveness results were more favorable toward
omalizumab, assuming larger HRQOL improvement with omali-
zumab than with standard therapy and a greater asthma mortal-
ity risk. The HRQOL improvement required to reduce the ICER
below £30,000 per QALY is similar to the improvement observed
for the hospitalization subgroup but more than double of that
observed for the overall population. Two main issues arise, ﬁrst
whether an improvement of 0.13 reﬂects the improvement
patients experience in clinical practice (compared with the
artiﬁcial setting of an RCT), and second, whether the EQ-5D orn the cost-effectiveness of omalizumab. The subgroups with
overlap the other subgroups and the overall population. EQ-
ost-effectiveness ratio; OCS, oral corticosteroid; QALY,
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of treatment. The ﬁrst issue is essentially an empirical question
that may be related to adherence and can be resolved by
comparing the HRQOL improvements observed in nonrandom-
ized evidence. For example, a statistically signiﬁcant improve-
ment of 0.14  0.23 from baseline was observed in a prospective
cohort study evaluating omalizumab in Belgium [34]. Another
observational study in Germany, however, did not ﬁnd a statisti-
cally signiﬁcant improvement in the EQ-5D values [35]. The
second issue is intrinsic to the NICE appraisal process. Although
generic measures may not capture all relevant dimensions or all
important changes for all conditions, cross-program assessments
of cost-effectiveness require a measure of health outcomes that
is applicable to all [36].
The ICER for omalizumab falls below £30,000 per QALY gained
if asthma mortality is above 1.7 deaths per 100 persons-years in
the overall adult population (vs. 0.4 per 100 persons-years in the
base case). The systematic review on asthma mortality found no
evidence to support a mortality risk of this magnitude. However,
the asthma-mortality risk needed to reduce the ICER in the
severe subgroups is much smaller and more in line with the
available evidence. The ICER also falls considerably if mortality
after a severe exacerbation is at least 2.478%. This implies that 2
to 3 asthma deaths would be expected per 100 severe exacer-
bations; however, there were 149 severe exacerbations recorded
in INNOVATE but no deaths attributable to asthma were observed
in INNOVATE. Although this is in a controlled RCT setting, the
mortality reported in Watson et al., at least for patients aged 45
years and older, is likely to be an overestimate. The advantage of
the Watson et al. data is that it distinguishes an increasing risk of
asthma death with age, when asthma mortality is known to
increase with age [37]. This is an advantage, however, only if
different recommendations are to be made by age. The next
hurdle would be to deﬁne age thresholds for which omalizumab
would be recommended as an option. This would leave NICE in a
situation similar to what motivated this appraisal in which
patients aged 12 years and older were recommended omalizu-
mab but not patients younger than 12 years.
Comparison with Other Studies and Previous TAs on
Omalizumab
Other peer-reviewed studies have previously examined the cost-
effectiveness of omalizumab in asthma using a decision model
broadly similar to the structure used here and assuming that the
beneﬁts of omalizumab were conferred through a reduction in
clinically signiﬁcant exacerbations and improvement in HRQOL
on a daily basis [9,11–13]. The entire licensed population, how-
ever, was the focus rather than subgroups. The ICERs ranged from
€31,209 per QALY gained for the Canadian setting under a health
care payer perspective [13] to $821,000 per QALY gained for the
United States under a societal perspective [11]. The differences in
the results between other studies and the one reported here are
mostly due to different sources used for asthma mortality and
HRQOL improvement conferred by omalizumab. The different
parameter inputs also explain the contrasting results with the
previous TAs on omalizumab (TA133 and TA201) [7,8]. The ICERs
for the entire population and for the hospitalization subgroup in
TA133 (patients 12 years and older) were £30,647 and £26,500 per
QALY gained, respectively, using effectiveness estimates from
INNOVATE and an asthma mortality of 3.108% per CSS exacer-
bation [7]. The ICERs for the entire 6- to 11-year-old population
and the hospitalization subgroup were £91,169 and £65,911 per
QALY gained, using effectiveness estimates from IA-05 EUP,
assuming no HRQOL improvement and an age-dependent asthma
mortality from Watson et al. [8,23]. This is consistent with the
results of the uncertainty and scenario analysis that showedconsiderable reductions in the ICER if the greater asthma mortal-
ity or HRQOL improvement with omalizumab are assumed.
Strengths and Limitations
This study reports policy-relevant results based on the ﬁrst
simultaneous appraisal of omalizumab for the entire licensed
population covering children, adolescents, and adults, which
ensured that previous uncertainties related to the different indi-
cations could be directly addressed and used to inform subsequent
recommendations for the UK NHS. This analysis addressed the key
areas of uncertainty identiﬁed in the previous appraisals with a
series of systematic reviews and subgroup and scenario analyses.
Systematic reviews were conducted to identify evidence on 1) the
mortality risk associated with asthma and the relationship
between mortality, age, and severity of exacerbations and 2) the
HRQOL improvement with omalizumab in both adults and ado-
lescents and children. Because the clinical trials enrolled a mixture
of patients uncontrolled at step 4 and step 5, patient subgroups
were deﬁned post hoc by stratifying patients according to different
indicators of asthma severity: hospitalizations, number of exacer-
bations in the past year, and maintenance OCS use. The relative
efﬁcacy and safety of omalizumab compared with OCS has been
examined by deﬁning a post hoc maintenance OCS subgroup
population. The hospitalization and three or more exacerbation
subgroups evaluated the cost-effectiveness of omalizumab in
patients with severely uncontrolled asthma. The impact of uncer-
tainty in the cost-effectiveness results has been assessed with
probabilistic sensitivity analysis and scenario analyses.
A limitation of this analysis is the assessment of costs and
health losses associated with maintenance OCS use. Given the
nonfeasibility of purposely building an economic model to assess
the costs and health outcomes associated with maintenance use
of OCS and the absence of economic evaluations comparing
steroids against any comparator for the treatment of asthma, a
scenario analysis used the published estimates of health losses
and costs due to OCS. This scenario required a number of
assumptions to be made, which may underpin the validity of
the estimates obtained. These include 1) that patients who do not
receive omalizumab will continue to receive maintenance OCS
for the remainder of their lifetime; 2) that the excess relative risk
attributable to OCS is based solely on current exposure to OCS,
and once patients discontinue OCS the excess relative risk
becomes negligible; and 3) that health losses expressed in
disability-adjusted life-years are equivalent to health losses
expressed in QALYs. Another limitation was the need to deﬁne
subgroup populations post hoc. As a result, the subgroup analy-
ses may have been underpowered to detect differences in treat-
ments, which, in turn, may have reduced the comparative
effectiveness and cost-effectiveness of omalizumab.
Implications for Policy
The NICE committee recommended omalizumab as a treatment
option for patients aged 6 years and older who need continuous
or frequent treatment with OCS under the PAS price. This
subgroup is broader than the maintenance OCS subgroup in this
study because it includes patients who received at least four
courses of OCS in the previous year. The hospitalization prereq-
uisite, which had been included in the recommendation of TA133
for adults and adolescents, was considered to provide a perverse
incentive for patients to let the condition worsen. An important
recommendation moving forward is the need to better target the
use of omalizumab to patients for whom it is likely to be both an
effective and cost-effective treatment. The results from these
analyses could be used to indicate the effect sizes required on the
basis of the current acquisition cost of omalizumab. Even with the
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 7 2 – 7 8 2 781PAS price, it is clear that omalizumab needs to be carefully targeted
to ensure value for money. Alternatively, further price reductions
could improve cost-effectiveness and could result in a larger
proportion of the population for whom it is indicated to beneﬁt.
Remaining Areas of Uncertainty for Future Research
The remaining areas of uncertainty follow from the key uncertain-
ties and limitations of this analysis. First, subgroup analyses should
be deﬁned a priori and adequately powered to detect the impact of
omalizumab on exacerbations and HRQOL. Second, the costs and
health losses associated with long-term use of OCS should be
subject of “targeted” assessment, which incorporated evidence from
RCTs as well as observational studies. The results of this work would
be useful for appraisals in a wide range of conditions given the large
number of indications for which long-term use of OCS is indicated.Acknowledgments
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